Selkirk Pharma Introduces ClinFAST™ to Expedite Fill/Finish for Clinical Trials
New
service ensures rapid delivery of small volume clinical trial materials,
solving a critical bottleneck in
drug development
Spokane, WA – February 12,
2025
– Selkirk Pharma, Inc., a privately held U.S. pharmaceutical manufacturer
specializing in the fill and finish of injectable drugs, including vaccines and
biological therapeutics, today announced the launch of ClinFAST™, a paradigm-shifting
service designed to assist clinical stage biotech and pharma companies with a
rapid fill/finish process for clinical trial supplies. By reducing production
timelines while maintaining high-quality standards, ClinFAST addresses a
significant challenge faced by drug developers—securing fill/finish capacity in
a market where small-batch projects are often deprioritized by larger contract
manufacturing organizations (CMOs).
“In clinical drug development,
time is everything. Delays in sterile fill/finish can mean missed trial
milestones and significant financial setbacks,” said Colleen Dixon, CEO of
Selkirk Pharma. “ClinFAST represents a significant advancement in our ability
to ensure biotech and pharma companies can access the high-quality drug product
manufacturing they need—without the typical wait times. Our experienced team,
best-in-class equipment, and commitment to excellence mean our clients can
trust us to help them stay on track and bring life-saving treatments to
patients faster.”
A Faster Path to Clinical
Trials Without Sacrificing Quality
The traditional fill/finish
landscape presents major hurdles for small-volume projects, with waiting
periods ranging from 6 to 12 months for an available slot. ClinFAST eliminates
these delays by running production processes in parallel and leveraging a templated
approach that streamlines each step—from compounding to final release. Selkirk
Pharma maintains an on-site inventory of ISO-sized vials, stoppers, filling
assemblies, and excipients, reducing the lead time required for sourcing
materials. The company also offers flexibility for clients to incorporate
customer-supplied materials that align with the ClinFAST process.
Key advantages of ClinFAST:
·
Rapid turnaround: Delivers clinical trial
materials in a fraction of the time required by larger CMOs.
·
Batch sizes up to 10,000 vials: Ideal for
liquid-filled vials used in Phase 1 and 2 trials.
·
High-yield processing: State-of-the-art
equipment minimizes line-loss and ensures consistent filled-container yields.
·
Scalability: Capable of supporting clients
beyond clinical trials with commercial-scale manufacturing capacity.
With ClinFAST, Selkirk Pharma
provides a dedicated solution to drug developers for meeting critical clinical
timelines. The company’s risk-based approach prioritizes efficiency without
compromising quality, ensuring that every project receives the attention it
deserves.
To learn more about Selkirk
Pharma’s available capacity, capabilities, and commitment to quality, please
contact Selkirk Pharma via selkirkpharma.com or
email [email protected].
About Selkirk Pharma
Selkirk Pharma, located in
Spokane, Washington, was founded by industry veterans with the vision to build
the world’s most reliable manufacturer of injectable drug products. We are
dedicated to quality and reliability while upholding a partnership philosophy
to ensure drug safety and availability. With an experienced team averaging over
15 years in the industry, our professionals are passionate about optimizing
fill and finish turn-around times and accelerating product release while never
compromising patient care. Selkirk is committed to delivering efficient,
high-quality, and innovative drug product manufacturing solutions to help biotech
and pharma companies achieve their clinical trial goals. For more information
about ClinFAST™ and Selkirk Pharma's services, visit www.selkirkpharma.com.
Contact:
Lonnie Barish, MBA
VP, Business Development &
Marketing
Selkirk Pharma
[email protected]
